Literature DB >> 10759720

Comparative analyses of megakaryocytes derived from cord blood and bone marrow.

R Miyazaki1, H Ogata, T Iguchi, S Sogo, T Kushida, T Ito, M Inaba, S Ikehara, Y Kobayashi.   

Abstract

Thrombocytopenia is typically observed in patients undergoing cord blood transplantation. We hypothesized that delayed recovery of the platelet count might be caused by defects in the megakaryocytic differentiation pathway of cord blood progenitors. To test this hypothesis, we compared the features of in vitro megakaryocytopoiesis between cord blood progenitors and those in bone marrow cells after isolation of CD34+ cells as progenitors. The proliferative responses of the progenitors in cord blood are higher than those in bone marrow cells in the presence of interleukin (IL)-3, stem cell factor (SCF) and thrombopoietin (TPO). However, the ability to generate mature megakaryocytes was higher in bone marrow progenitors than in cord blood in the same in vitro culture system, when examined by the expression of CD41, polyploidy and proplatelet formation. Furthermore, an earlier induction of c-mpl protein, a receptor for TPO, was observed in the progenitors from bone marrow than in those from cord blood in the presence of SCF and IL-3. Therefore, the ability to generate mature megakaryocytes in bone marrow progenitors is superior to that in cord blood, and the delayed engraftment of platelets after cord blood transplantation might be attributed to the features of cord blood megakaryocyte progenitors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10759720     DOI: 10.1046/j.1365-2141.2000.01854.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Differential regulation of MCM7 and its intronic miRNA cluster miR-106b-25 during megakaryopoiesis induced polyploidy.

Authors:  Srijan Haldar; Anita Roy; Subrata Banerjee
Journal:  RNA Biol       Date:  2014       Impact factor: 4.652

Review 2.  Towards the Manufacture of Megakaryocytes and Platelets for Clinical Application.

Authors:  Anja Baigger; Rainer Blasczyk; Constanca Figueiredo
Journal:  Transfus Med Hemother       Date:  2017-05-23       Impact factor: 3.747

Review 3.  Recent developments in ex vivo platelet production.

Authors:  Retno Wahyu Nurhayati; Yoshihiro Ojima; Masahito Taya
Journal:  Cytotechnology       Date:  2016-03-22       Impact factor: 2.058

4.  Induction of megakaryocytic differentiation in primary human erythroblasts: a physiological basis for leukemic lineage plasticity.

Authors:  A N Goldfarb; D Wong; F K Racke
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 5.  In vitro megakaryocyte production and platelet biogenesis: state of the art.

Authors:  Jo-Anna Reems; Nicolas Pineault; Sijie Sun
Journal:  Transfus Med Rev       Date:  2010-01

Review 6.  Manipulating megakaryocytes to manufacture platelets ex vivo.

Authors:  P Karagiannis; K Eto
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

Review 7.  Transcription factors in late megakaryopoiesis and related platelet disorders.

Authors:  M R Tijssen; C Ghevaert
Journal:  J Thromb Haemost       Date:  2013-04       Impact factor: 5.824

8.  Development of an ex vivo xenogeneic bone environment producing human platelet-like cells.

Authors:  Shingo Fujiyama; Nobuyasu Hori; Toshiyuki Sato; Shin Enosawa; Mitsuru Murata; Eiji Kobayashi
Journal:  PLoS One       Date:  2020-04-07       Impact factor: 3.240

Review 9.  The incredible journey: From megakaryocyte development to platelet formation.

Authors:  Kellie R Machlus; Joseph E Italiano
Journal:  J Cell Biol       Date:  2013-06-10       Impact factor: 10.539

10.  Metabolite Patterns in Human Myeloid Hematopoiesis Result from Lineage-Dependent Active Metabolic Pathways.

Authors:  Lars Kaiser; Helga Weinschrott; Isabel Quint; Markus Blaess; René Csuk; Manfred Jung; Matthias Kohl; Hans-Peter Deigner
Journal:  Int J Mol Sci       Date:  2020-08-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.